Skip to main content
    G

    GT Biopharma Inc (GTBP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.54
    -0.18 (-4.97%)

    Market Cap: $7.67M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    GT Biopharma Inc (GTBP) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to GT Biopharma are In8bio (INAB), Tempest Therapeutics (TPST) and Theriva Biologics (TOVX). By market cap, GT Biopharma ranks 7th of the 13 companies on this page; Marker Therapeutics (MRKR) is the largest at $14.51M.

    Peer Comparison

    GTBP's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    GT Biopharma (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    In8bio Inc (INAB)$8.86MN/AN/A0.0%N/A0.0%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    FibroBiologics, Inc. Common Stock (FBLG)$6.57MN/AN/A0.0%N/A0.0%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    Intensity Therapeutics, Inc. Common stock (INTS)$10.17MN/AN/A0.0%N/A0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Traws Pharma Inc (TRAW)$3.86MN/AN/A0.0%N/A-100.0%0.00%
    GRI Bio Inc. (GRI)$3.72MN/AN/A0.0%N/A0.0%0.00%
    Peer median$7.83MN/A15.5x0.0%-101.0%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to GT Biopharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    In8bio Inc (INAB)
    IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers...
    INAB competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    FibroBiologics, Inc. Common Stock (FBLG)
    FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology...
    FBLG competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    Intensity Therapeutics, Inc. Common stock (INTS)
    Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems.
    INTS competitors
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Traws Pharma Inc (TRAW)
    Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
    TRAW competitors
    GRI Bio Inc. (GRI)
    GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology.
    GRI competitors

    Frequently Asked Questions About GTBP

    Who are GT Biopharma's main competitors?

    The companies most similar to GT Biopharma include In8bio (INAB), Tempest Therapeutics (TPST), Theriva Biologics (TOVX), Tscan Therapeutics (TCRX) and FibroBiologics, Inc. Common Stock (FBLG), listed from the closest match.

    Who is GT Biopharma's biggest competitor?

    Marker Therapeutics (MRKR) is the largest of the similar companies at $14.51M; In8bio (INAB) is the closest match by business profile, size, sector and industry.

    How does GTBP stock compare with its competitors?

    GTBP's net margin is 0.0% against a peer median of 0.0%.

    Which of GT Biopharma's competitors pays a higher dividend?

    GT Biopharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is GT Biopharma bigger than its competitors?

    No. GT Biopharma is 7th by market cap among the 13 companies on this page; the largest is Marker Therapeutics (MRKR) at $14.51M.